Regulus Therapeutics (RGLS) Reports In-Line Q2 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins